<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Gliclazide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01120</strong>&#160; (APRD00460)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (<span class="caps">NIDDM</span>). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating &#946; cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic &#946; cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01120/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01120/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01120.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01120.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01120.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01120.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01120.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01120">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gliclazida</td><td>Spanish</td><td>INN</td></tr><tr><td>Gliclazidum</td><td>Latin</td><td>INN</td></tr><tr><td>N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Diamicron</td><td>Servier</td></tr><tr><td>Diamicron MR</td><td>Servier</td></tr><tr><td>Glimicron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mylan-Gliclazide</td><td>Mylan</td></tr><tr><td>Nordialex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>PMS-Gliclazide</td><td>Pharmascience</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypoglycemic-agents">Hypoglycemic Agents</a></li>
<li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>21187-98-4</td></tr><tr><th>Weight</th><td>Average: 323.411<br>Monoisotopic: 323.130362243</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>BOVGTQGAOIONJV-BETUJISGNA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)/t12-,13+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-2-yl]-1-(4-methylbenzenesulfonyl)urea</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCC[C@]1([H])CN(C2)NC(=O)NS(=O)(=O)C1=CC=C(C)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzenesulfonamides</td></tr><tr><th>Direct parent</th><td>Benzenesulfonamides</td></tr><tr><th>Alternative parents</th><td>Toluenes; Sulfonylureas; Sulfonamides; Sulfonyls; Semicarbazides; Pyrrolidines; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>sulfonylurea; toluene; cyclic alcohol; pyrrolidine; sulfonyl; semicarbazide; sulfonamide; sulfonic acid derivative; polyamine; amine; hydrazine derivative; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of NIDDM in conjunction with diet and exercise. </td></tr><tr><th>Pharmacodynamics</th><td>Gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates &#946; cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall, it potentiates insulin release and improves insulin dynamics.</td></tr><tr><th>Mechanism of action</th><td>Gliclazide binds to the &#946; cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the &#946; cells. This opens voltage-dependent calcium channels in the &#946; cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.</td></tr><tr><th>Absorption</th><td>Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>94%, highly bound to plasma proteins</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Extensively metabolized in the liver. Less than 1% of the orally administered dose appears unchanged in the urine. Metabolites include oxidized and hydroxylated derivates, as well as glucuronic acid conjugates. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Gliclazide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET00202">7-&#946;-Hydroxygliclazide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/203">Details</a></td></tr><tr><td>Gliclazide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET00203">6-&#946;-Hydroxygliclazide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/204">Details</a></td></tr><tr><td>Gliclazide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li></ul></td><td><a href="/metabolites/DBMET00204">Methylhydroxygliclazide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/205">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00204">Methylhydroxygliclazide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01328">Carboxygliclazide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1508">Details</a></td></tr><tr><td>Gliclazide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET01329">7-&#945;-Hydroxygliclazide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1509">Details</a></td></tr><tr><td>Gliclazide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET01330">6-&#945;-Hydroxygliclazide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1510">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) and also in the feces (10-20%).</td></tr><tr><th>Half life</th><td>10.4 hours. Duration of action is 10-24 hours. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=3000 mg/kg (orally in mice). Gliclazide and its metabolites may accumulate in those with severe hepatic and/or renal dysfunction. Symptoms of hypoglycemia include: dizziness, lack of energy, drowsiness, headache and sweating.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Gliclazide Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9944</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8445</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6543</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6982</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8619</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.931</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Substrate</td>
        <td>0.6226</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6925</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9218</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8751</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8047
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7944
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7997
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0016 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5992
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8064
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li><a href="http://www.servier.ca/">Servier Canada</a></li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>80 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>30 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>60 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01294">Bismuth Subsalicylate</a></td><td>The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00636">Clofibrate</a></td><td>Clofibrate may increase the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Dicumarol may increase the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01296">Glucosamine</a></td><td>Possible hyperglycemia</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01397">Magnesium salicylate</a></td><td>The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00812">Phenylbutazone</a></td><td>Phenylbutazone increases the effect of the hypoglycemic agent</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>The beta-blocker, practolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB01398">Salicylate-sodium</a></td><td>The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB01399">Salsalate</a></td><td>The salicylate, salsalate, increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB00052">Somatropin recombinant</a></td><td>Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The beta-blocker, timolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01401">Trisalicylate-choline</a></td><td>The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, gliclazide.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take without regard to meals. A consistent diet is recommended to reduce the risk of hypoglycemia.</li></ul></td></tr></tbody></table>